{"id":"vtama","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Pruritus"}]},"_chembl":null,"_dailymed":{"setId":"9309d20f-8cd4-4c96-93fa-7f730e83c7ab","title":"VTAMA (TAPINAROF) CREAM [ORGANON LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"VTAMA (tapinarof) is a selective retinoid X receptor (RXR) agonist applied topically to affected skin. By activating RXR, it modulates gene expression involved in keratinocyte differentiation and immune regulation, reducing the hyperproliferation and inflammatory cascade characteristic of psoriasis plaques.","oneSentence":"VTAMA is a topical retinoid that binds to and activates retinoid X receptors (RXR) to promote skin cell differentiation and reduce inflammation in psoriasis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:40:51.443Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Plaque psoriasis"}]},"trialDetails":[{"nctId":"NCT06742957","phase":"PHASE3","title":"Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2024-12-17","conditions":"Plaque Type Psorisis","enrollment":560},{"nctId":"NCT05789576","phase":"PHASE4","title":"A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2023-03-13","conditions":"Psoriasis","enrollment":31},{"nctId":"NCT05680740","phase":"PHASE4","title":"A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2022-12-27","conditions":"Psoriasis","enrollment":34},{"nctId":"NCT06103695","phase":"PHASE4","title":"Vtama in Psoriasis Patients Being Treated With Biologics.","status":"COMPLETED","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2023-02-27","conditions":"Psoriasis","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"VTAMA®","genericName":"VTAMA®","companyName":"Teva Pharmaceuticals USA","companyId":"teva-pharmaceuticals-usa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VTAMA is a topical retinoid that binds to and activates retinoid X receptors (RXR) to promote skin cell differentiation and reduce inflammation in psoriasis. Used for Plaque psoriasis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}